PL3268391T3 - Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn - Google Patents

Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn

Info

Publication number
PL3268391T3
PL3268391T3 PL16719896T PL16719896T PL3268391T3 PL 3268391 T3 PL3268391 T3 PL 3268391T3 PL 16719896 T PL16719896 T PL 16719896T PL 16719896 T PL16719896 T PL 16719896T PL 3268391 T3 PL3268391 T3 PL 3268391T3
Authority
PL
Poland
Prior art keywords
antagonsits
fcrn
methods
serum levels
containing agents
Prior art date
Application number
PL16719896T
Other languages
English (en)
Polish (pl)
Inventor
Nicolas G.H. Ongenae
Torsten Dreier
Peter Ulrichts
Johannes De Haard
Christophe Blanchetot
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of PL3268391T3 publication Critical patent/PL3268391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16719896T 2015-03-09 2016-03-08 Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn PL3268391T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562130076P 2015-03-09 2015-03-09
EP16719896.9A EP3268391B1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
PCT/IB2016/000398 WO2016142782A1 (en) 2015-03-09 2016-03-08 Methods of reducing serum levels of fc-containing agents using fcrn antagonsits

Publications (1)

Publication Number Publication Date
PL3268391T3 true PL3268391T3 (pl) 2022-01-03

Family

ID=55863122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16719896T PL3268391T3 (pl) 2015-03-09 2016-03-08 Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn

Country Status (19)

Country Link
US (1) US20160264669A1 (https=)
EP (2) EP4006051A1 (https=)
JP (6) JP2018509413A (https=)
KR (1) KR102720769B1 (https=)
AU (2) AU2016230827B2 (https=)
CA (1) CA2978253A1 (https=)
DK (1) DK3268391T3 (https=)
EA (1) EA038178B1 (https=)
ES (1) ES2882999T3 (https=)
HU (1) HUE056775T2 (https=)
IL (2) IL295425A (https=)
LT (1) LT3268391T (https=)
MX (2) MX386491B (https=)
MY (1) MY188761A (https=)
PL (1) PL3268391T3 (https=)
PT (1) PT3268391T (https=)
SG (2) SG11201707053SA (https=)
WO (1) WO2016142782A1 (https=)
ZA (1) ZA202109042B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112142843B (zh) 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
KR20250052465A (ko) * 2015-01-30 2025-04-18 모멘타 파머슈티컬스 인코포레이티드 ＦｃＲｎ 항체 및 이의 사용 방법
MY188761A (en) * 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists
AU2017292184A1 (en) 2016-07-08 2019-02-07 Staten Biotechnology B.V. Anti-Apoc3 antibodies and methods of use thereof
GB201618424D0 (en) * 2016-11-01 2016-12-14 Argenix Bvba Treatment of antibody mediated disease
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
US12240875B2 (en) * 2017-12-08 2025-03-04 argenx BV Use of FCRN antagonists for treatment of generalized myasthenia gravis
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
WO2020148336A1 (en) * 2019-01-16 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
CN114126647A (zh) * 2019-06-07 2022-03-01 阿尔金克斯有限公司 适用于皮下施用的FcRn抑制剂的药物制剂
EP4004039A2 (en) * 2019-07-25 2022-06-01 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
BR112022013554A2 (pt) 2020-01-08 2022-09-06 argenx BV Métodos para tratar distúrbios do pênfigo
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US20230220069A1 (en) * 2020-06-17 2023-07-13 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of gene therapy patients
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250136699A1 (en) * 2021-08-13 2025-05-01 Jiangsu Biojetay Biotechnology Co., Ltd. Antibodies specifically recognizing fcrn and uses thereof
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
KR20250109198A (ko) * 2022-11-14 2025-07-16 아르젠엑스 비브이 Fcrn 길항제 분자 및 이의 사용 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6128119A (en) 1997-01-10 2000-10-03 Asahi Kogaku Kogyo Kabushiki Kaisha Beam shaping optical system
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6992234B2 (en) * 2000-11-06 2006-01-31 The Jackson Laboratory FcRn-based therapeutics for the treatment of auto-immune disorders
CA2467781C (en) 2000-11-20 2014-09-23 Canadian Blood Services Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004062619A2 (en) 2003-01-13 2004-07-29 Macrogenics, Inc. SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2006130834A2 (en) * 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
MY173526A (en) * 2009-03-25 2020-01-31 Genentech Inc Novel anti-?5?1 antibodies and uses thereof
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
CA2853637C (en) * 2011-10-26 2023-04-04 Novartis Ag Anti-canine cd20 monoclonal antibodies and methods of use
EP2780463A4 (en) * 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
DK3421486T5 (da) 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
CN112142843B (zh) * 2013-12-24 2024-10-18 阿尔金克斯有限公司 FcRn拮抗剂及使用方法
MY188761A (en) * 2015-03-09 2021-12-29 Argenx Bvba Method of reducing serum levels of fc-containing agents using fcrn antagonists

Also Published As

Publication number Publication date
AU2021277720B2 (en) 2025-03-27
DK3268391T3 (da) 2021-09-13
MY188761A (en) 2021-12-29
JP7403575B2 (ja) 2023-12-22
CA2978253A1 (en) 2016-09-15
JP7050191B2 (ja) 2022-04-07
AU2016230827A1 (en) 2017-08-24
EP3268391A1 (en) 2018-01-17
JP2026012786A (ja) 2026-01-27
IL254403B (en) 2022-09-01
EA038178B1 (ru) 2021-07-20
MX2021011633A (es) 2021-10-22
JP2024037846A (ja) 2024-03-19
HUE056775T2 (hu) 2022-03-28
US20160264669A1 (en) 2016-09-15
AU2021277720A1 (en) 2021-12-23
EP4006051A1 (en) 2022-06-01
JP2022084868A (ja) 2022-06-07
EP3268391B1 (en) 2021-08-11
WO2016142782A1 (en) 2016-09-15
JP2021073282A (ja) 2021-05-13
ES2882999T3 (es) 2021-12-03
EA201791984A1 (ru) 2017-12-29
KR102720769B1 (ko) 2024-10-22
NZ734416A (en) 2024-12-20
MX2017011534A (es) 2018-04-10
ZA202109042B (en) 2025-01-29
JP2018509413A (ja) 2018-04-05
KR20170131463A (ko) 2017-11-29
BR112017019191A2 (pt) 2018-05-02
AU2016230827B2 (en) 2021-10-28
JP7823011B2 (ja) 2026-03-03
PT3268391T (pt) 2021-08-19
IL295425A (en) 2022-10-01
SG11201707053SA (en) 2017-09-28
JP2022105084A (ja) 2022-07-12
LT3268391T (lt) 2021-09-10
JP7391132B2 (ja) 2023-12-04
IL254403A0 (en) 2017-11-30
SG10201908259WA (en) 2019-10-30
MX386491B (es) 2025-03-18

Similar Documents

Publication Publication Date Title
IL254403A0 (en) Methods for lowering the amount of fc-containing substances in the serum by using fcrn antibodies
IL252837A0 (en) fcrn antibodies and methods of using them
LT3368688T (lt) Kompozicijos ir būdai, skirti modifikuotų citozinų nustatymui sekvenavimu
IL255406A0 (en) A method for growing in the culture of Acramansia
PL3201361T3 (pl) Sposoby ilościowego oznaczania pozakomórkowego DNA
HUE065780T2 (hu) FCRN ellenanyagok és eljárások alkalmazásukra
EP3297661A4 (en) Method of improving characteristics of proteins
GB201515557D0 (en) Method of sequencing
GB201515558D0 (en) Method of sequencing
IL249729A0 (en) Methods and materials for cleaning proteins
IL254765A0 (en) A method for the monomerization of recombinant antibody molecules
PL3189336T3 (pl) Sposób określania ryzyka stanu przedrzucawkowego
IL255094A0 (en) A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody
GB201522552D0 (en) Method of improving adhesion
GB201604627D0 (en) Improved method of FT-IMS
SG11201800894SA (en) Method for parallel quantification of protein variant
IL252712A0 (en) Method for protein production
SG10201508927SA (en) Protein crystal
TH1601002706A (th) แอนทิบอดีที่จำเพาะต่อ FcRn
GB201611950D0 (en) Construction panel and method for its manufacture
GB201503485D0 (en) Methods & Kits